Citation Impact
Citing Papers
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology.
1999
The prognostic value of baseline erosions in undifferentiated arthritis
2009
Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis
2018 StandoutNobel
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment
2010
The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis
1998
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
2009
Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects
2007
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
2013
The role of the T cell in autoimmune inflammation.
2005
Re-establishing immunological self-tolerance in autoimmune disease
2012 StandoutNobel
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality
2015 StandoutNobel
The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis
2010
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
2009
CTLA4Ig: Bridging the Basic Immunology with Clinical Application
2006
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
2014
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
2003 Standout
A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
1999 Standout
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
2010
The Systemic Amyloidoses
1997 Standout
Long‐term prospective trial of low‐dose methotrexate in rheumatoid arthritis
1988
Small-Vessel Vasculitis
1997 Standout
New therapies for treatment of rheumatoid arthritis
2007
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled study
2006
Rheumatoid arthritis
2016 Standout
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
2011 StandoutNature
Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year
1998
Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis
2007
Juvenile idiopathic arthritis
2007 Standout
Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
2003
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
1995 Standout
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Patient-Driven Outcomes in Rheumatoid Arthritis
2009
Co‐stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
2005 StandoutNobel
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
1999 Standout
CEACAM1: contact-dependent control of immunity
2006
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
2007
Systemic sclerosis
2017 Standout
Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis
2011
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
2009
Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family
2011
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
2004 Standout
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
2008
Methotrexate in Resistant Juvenile Rheumatoid Arthritis
1992
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
1998
Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis
2012
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
2006
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
The effects of drug therapy on radiographic progression of rheumatoid arthritis. results of a 36‐week randomized trial comparing methotrexate and auranofin
1993
Abatacept for severe anti–tumor necrosis factor α refractory juvenile idiopathic arthritis–related uveitis
2010
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
2009
How antirheumatic drugs protect joints from damage in rheumatoid arthritis
2008
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
2003 Standout
Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-?, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures
1992
Abatacept
2006
Forget personalised medicine and focus on abating disease activity
2012
Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
2008
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trial
2005
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
2006
T cell–directed therapies: lessons learned and future prospects
2006
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
2016
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
1999
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
Graves' Ophthalmopathy
2010 Standout
Wegener Granulomatosis: An Analysis of 158 Patients
1992 Standout
MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis
2006
Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications
1996
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
2000 Standout
Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.
1998
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
2006
Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?
1998
The Antiphospholipid Syndrome
2002 Standout
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
2010
Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study
2009
Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty‐eight–week randomized, double‐blind trial
1991
Systemic Lupus Erythematosus
2011 Standout
The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial
2010
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
2008
Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis
2013
The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases
1996
The Use of Low Dose Methotrexate in Refractory Sarcoidosis
1990
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
2007
Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
2003
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Type 1 diabetes
2013 Standout
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
2007
Results of a two‐year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate
2008
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Ulcerative colitis
2016 Standout
Abatacept therapy and safety management
2009
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
2000 Standout
Severe Adverse Cutaneous Reactions to Drugs
1994 Standout
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
2008
Sarcoidosis
1997 Standout
Rheumatoid arthritis
2010 Standout
Tryptophan degradation in autoimmune diseases
2007
Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies
2015
Clinical Trials of Transplant Tolerance: Slow But Steady Progress
2003
Costimulation Blockade with Belatacept in Renal Transplantation
2005 Standout
Multiple Sclerosis
2000 Standout
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
2009
Long‐Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis
1992
Baricitinib in Patients with Refractory Rheumatoid Arthritis
2016
Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept
2008
Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review
2010
Low‐dose methotrexate compared with auranofin in adult rheumatoid arthritis
1990
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
2014
Cytokines in the pathogenesis of rheumatoid arthritis
2007 Standout
Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy
2014
T-cell-targeted therapies in rheumatoid arthritis
2006
Current management of juvenile idiopathic arthritis
2006
Immunosuppressive Drugs for Kidney Transplantation
2004 Standout
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Biologic therapy and pregnancy outcomes in women with rheumatic diseases
2009
Exploring the full spectrum of macrophage activation
2008 Standout
Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
2008
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Rheumatoid Arthritis
2008
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
2013 StandoutNobel
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one‐year double‐blind study in 174 patients
2002
Pre-eclampsia
2015 Standout
Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two
1993
Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis
1994 StandoutScience
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Methotrexate in Rheumatoid Arthritis
1987
Response rates and survival in primary systemic amyloidosis
1991
The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritis
1986
CD4+CD25−LAG3+regulatory T cells controlled by the transcription factor Egr-2
2009 StandoutNobel
Intact B 7‐H 3 signaling promotes allograft prolongation through preferential suppression of T h1 effector responses
2012
Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
2008
Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges
2005
Advances in targeted therapeutic agents
2010
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
2010
Novel TNF antagonists for the treatment of rheumatoid arthritis
2009
Dietary Folic Acid Promotes Survival of Foxp3+ Regulatory T Cells in the Colon
2012 StandoutNobel
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
2008
Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
2006
Low‐dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. a twenty‐four—week controlled clinical trial
1987
Methotrexate Induces Clinical and Histologic Remission in Patients with Refractory Inflammatory Bowel Disease
1989
Methotrexate in Rheumatoid Arthritis
1987
Disease activity measures for rheumatoid arthritis.
2008
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
2007
Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis
1993 Science
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Monomeric Fc Fusions
2006
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
2012 StandoutNobel
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
Generic quality-of-life assessment in rheumatoid arthritis.
2007
Weekly Pulse Methotrexate in Rheumatoid Arthritis
1985
Works of Michael E. Luggen being referenced
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
2005
Early undifferentiated connective tissue disease. IV. Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of patients with well‐established connective tissue diseases: Followup analyses in patients with unexplained polyarthritis and patients with rheumatoid arthritis at baseline
1996
A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis
1988
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion
2002
Unusual longevity in primary systemic amyloidosis: a 19-year survivor
1989
Prenatal Screening for Anticardiolipin Antibody
1990
Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis
2007
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
2007
Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A Controlled Clinical Trial
1985
The evolution of Raynaud's phenomenon: a longterm prospective study.
1995
T Cell Costimulation: A Rational Target in the Therapeutic Armamentarium for Autoimmune Diseases and Transplantation
2006
Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease.
1991
Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases.
1991